The European Council and the European Parliament reached a provisional political agreement on 7 May 2026 to delay enforcement of the AI Act’s high-risk obligations by between 16 and 24 months. Stand-alone high-risk AI systems listed in Annex III now apply from 2 December 2027. AI embedded in regulated products that already require third-party conformity assessment now applies from 2 August 2028. Both categories were originally due to apply on 2 August 2026.
Article 6(1) of the AI Act is the provision that matters for BCI compliance teams. It covers AI inside CE-marked medical devices regulated under the Medical Device Regulation and the In Vitro Diagnostic Regulation. Class IIb and Class III medical devices under MDR, plus Class C and Class D in vitro diagnostics under IVDR, all qualify. Most clinical-stage cortical, spinal-cord-stimulation, and vagus-nerve-stimulation implants fall in those classes. Today’s deal pushes their AI Act compliance date from 2 August 2026 to 2 August 2028. MDR and IVDR obligations are unchanged.
The Digital Omnibus on AI also extends regulatory exemptions originally granted to small and medium enterprises to a broader category of small mid-caps. It reinforces the powers of the AI Office. It reduces governance fragmentation between national regulators. And it adds a new prohibition on AI practices that generate non-consensual sexual or intimate content, separate from the medical-device track. The Commission’s case for the package is that the harmonised standards and conformity-assessment tools regulated-product manufacturers need to demonstrate compliance were not going to be ready in time for 2 August 2026.
Why the timing slipped
The Commission proposed the Digital Omnibus in early 2026 after industry feedback that the compliance infrastructure for the embedded-product track was running late. The first trilogue session on 28 April failed without agreement on the timeline package. The 7 May session reached agreement after both bodies conceded ground. The deal still requires formal endorsement by Council and Parliament before legal-linguistic revision and adoption, which the Council expects in the coming weeks.
Who it changes the calendar for
ONWARD Medical, in Eindhoven, has the ARC-EX commercial product already inside MDR scope and the implantable ARC-IM in pivotal enrolment. INBRAIN Neuroelectronics, in Barcelona, completed first-in-human enrolment of its graphene cortical interface last month and holds an FDA Breakthrough Device Designation for Parkinson’s. CorTec, in Freiburg, is in pivotal enrolment for the Brain Interchange and was granted FDA Breakthrough Designation for stroke rehabilitation in April. Science Corporation’s PRIMA visual prosthesis is awaiting a CE Mark decision in 2026. None of those four loses any MDR or IVDR obligation under the deal. All four gain two years on the parallel AI Act high-risk classification, which had been adding data governance, transparency, human oversight, risk management, and post-market monitoring requirements on top of the existing medical-device track.
Synchron, Neuralink, Paradromics, and Precision Neuroscience get the same calendar shift even though none of them have launched in the EU yet. The AI Act timeline previously sat ahead of the MDR conformity-assessment bottleneck for these companies. It now sits parallel or behind. EU market-entry strategy can sequence MDR compliance first and AI Act compliance during or after.
Vermont and Brussels in the same week
Vermont’s H.814 cleared the State Senate on 6 May as a recognition-only neural rights statute, with the enforcement layer stripped in House committee. Brussels delayed the AI Act’s high-risk obligations on 7 May. Two of the four jurisdictional postures the Dargentic Neurotechnology Report (Spring 2026) maps for global neural data regulation moved in the same direction in seven days. The state-patchwork posture is now lighter than its proponents had hoped. The horizontal-regulator posture is now slower than its critics had feared. BCI compliance teams have less to do this year, in two of the four major regulatory frames, than they were planning for at the start of the quarter.
Sources: European Council press release, 7 May 2026. IAPP analysis on the Omnibus deal. Lewis Silkin commentary on the agreement.